CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishBackground: Adult mesenchymal stem cells (MSC) repair infarcted hearts mainly through cytoprotective paracrine mechanisms. Recently, MSC of fetal origin have been isolated from human amniotic membrane (A-MSC) but it is unknown if A-MSC can mediate cytoprotection and which pathways are eventually involved. Methods: A-MSC were isolated from human term placenta. Rat neonatal cardiomyocytes (H9c2) were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation in the presence of control medium (CTRL-M) or conditioned medium from A-MSC (A-MSC-CM). H9c2 viability was evaluated by MTS assay. Apoptosis was measured by TUNEL staining and by Caspase 3 activation (colorimetric assay and Western Blot). SAPK/JNK and p38 MAPK activation was analyzed by Western blotting. We used RT-PCR to evaluate pro- and anti-apoptotic genes in H9c2 cells and known cytoprotective factors in A-MSC. Results: Compared with CTRL-M, A-MSC-CM remarkably increased viability of H9c2 by 45% (p<0.001) and significantly reduced the number of TUNEL positive nuclei by 91% (p<0.001). Furthermore, both colorimetric and Western Blot assay showed that A-MSC-CM prevented Caspase 3 cleavege (p= n.s. vs normoxia). The hypoxia/reoxygenation induced a marked activation of SAPK/JNK and p38 MAPK that was strongly limited by A-MSC-CM. Furthermore, the A-MSC-CM increased the expression of Bcl-2 and Stat3 and inhibited transcription of TNF-α and FasL compared with CTRL-M. Finally, we documented that A-MSC express cytoprotective factors such as PDGF-β , BMP2, EPO, IGF-1, FGF2 and VEGF. Conclusions: We demonstrated that A-MSC express several cytoprotective factors and that A-MSC-CM remarkably protects cardiac myocytes against hypoxia/reoxygenation damage, through the inhibition of SAPK/JNK and p38 MAPK pro-apoptotic pathways. A-MSC-CM also mediates the over-expression of anti-apoptotic genes Bcl-2 and Stat3 and the downregulation of pro-apoptotic factors TNF-α and FasL. A-MSC theraphy may represent a novel and powerful approach for cardioprotection in ischemic heart disease.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Soluble factors released by human mesenchymal stem cells of fetal origin lead to cardiomyocyte protection through the inhibition of pro-apoptotic signaling | |
| Autori: | ||
| Data di pubblicazione: | 2010 | |
| Rivista: | ||
| Abstract: | Background: Adult mesenchymal stem cells (MSC) repair infarcted hearts mainly through cytoprotective paracrine mechanisms. Recently, MSC of fetal origin have been isolated from human amniotic membrane (A-MSC) but it is unknown if A-MSC can mediate cytoprotection and which pathways are eventually involved. Methods: A-MSC were isolated from human term placenta. Rat neonatal cardiomyocytes (H9c2) were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation in the presence of control medium (CTRL-M) or conditioned medium from A-MSC (A-MSC-CM). H9c2 viability was evaluated by MTS assay. Apoptosis was measured by TUNEL staining and by Caspase 3 activation (colorimetric assay and Western Blot). SAPK/JNK and p38 MAPK activation was analyzed by Western blotting. We used RT-PCR to evaluate pro- and anti-apoptotic genes in H9c2 cells and known cytoprotective factors in A-MSC. Results: Compared with CTRL-M, A-MSC-CM remarkably increased viability of H9c2 by 45% (p<0.001) and significantly reduced the number of TUNEL positive nuclei by 91% (p<0.001). Furthermore, both colorimetric and Western Blot assay showed that A-MSC-CM prevented Caspase 3 cleavege (p= n.s. vs normoxia). The hypoxia/reoxygenation induced a marked activation of SAPK/JNK and p38 MAPK that was strongly limited by A-MSC-CM. Furthermore, the A-MSC-CM increased the expression of Bcl-2 and Stat3 and inhibited transcription of TNF-α and FasL compared with CTRL-M. Finally, we documented that A-MSC express cytoprotective factors such as PDGF-β , BMP2, EPO, IGF-1, FGF2 and VEGF. Conclusions: We demonstrated that A-MSC express several cytoprotective factors and that A-MSC-CM remarkably protects cardiac myocytes against hypoxia/reoxygenation damage, through the inhibition of SAPK/JNK and p38 MAPK pro-apoptotic pathways. A-MSC-CM also mediates the over-expression of anti-apoptotic genes Bcl-2 and Stat3 and the downregulation of pro-apoptotic factors TNF-α and FasL. A-MSC theraphy may represent a novel and powerful approach for cardioprotection in ischemic heart disease. | |
| Handle: | http://hdl.handle.net/11571/220710 | |
| Appare nelle tipologie: | 4.1 Contributo in Atti di convegno |
File in questo prodotto:
Copyright © 2022